Analyst consensus rating
Oncolytics Biotech Analyst Rating: Buy
ONCY is rated Buy by 6 analysts with a $4.25 target. As of 2026-09-02.
Direct answer
Oncolytics Biotech's consensus rating is Buy.
6 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.25.
Forecast evidence checked September 2, 2026.
Get free Oncolytics Biotech email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.88
- Average price target
- $4.25
- High price target
- $6.02
- Low price target
- $2.93
- Low target gap
- +231.3%
- Target upside
- +380.7%
- High target gap
- +581.3%
- Target range width
- 350.1%
- Consensus rating
- Buy
- Analysts
- 6
- Evidence date
- September 2, 2026
- Valid through
- September 9, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Oncolytics Biotech?
Oncolytics Biotech has a verified Buy consensus. The same dataset has an average price target of $4.25.
How far are Oncolytics Biotech's low and high targets from the recorded price?
The low target implies +231.3%, while the high target implies +581.3%.
How many analysts are included in Oncolytics Biotech's consensus?
The verified consensus includes 6 analysts.
How is Oncolytics Biotech's target upside or downside calculated?
The average target of $4.25 is divided by the recorded price of $0.88, then one is subtracted to produce +380.7%. This does not guarantee a future return.
When was Oncolytics Biotech's analyst forecast verified?
The data was verified on 2026-09-02. The dataset is valid through 2026-09-09.